- Stocks
- Healthcare
- NASDAQ: SRPT

Price (delayed)

$143.94

Market cap

$13.61B

P/E Ratio

351.07

Dividend/share

N/A

EPS

$0.41

Enterprise value

$14.56B

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going

The EPS has soared by 107% from the previous quarter and by 103% YoY

The net income has soared by 103% QoQ and by 102% YoY

Sarepta Therapeutics's quick ratio has decreased by 26% YoY and by 8% from the previous quarter

SRPT's debt is up by 7% year-on-year

What are the main financial stats of SRPT

Market
Valuations
Earnings

Shares outstanding

94.52M

Market cap

$13.61B

Enterprise value

$14.56B

Price to earnings (P/E)

351.07

Price to book (P/B)

14.05

Price to sales (P/S)

9.64

EV/EBIT

427.42

EV/EBITDA

159.76

EV/Sales

10.37

Revenue

$1.4B

EBIT

$34.06M

EBITDA

$91.13M

Free cash flow

-$632.74M

Per share
Balance sheet
Liquidity

EPS

$0.41

Free cash flow per share

-$6.73

Book value per share

$10.24

Revenue per share

$14.93

TBVPS

$34.31

Total assets

$3.22B

Total liabilities

$2.26B

Debt

$1.38B

Equity

$961.19M

Working capital

$1.86B

Debt to equity

1.44

Current ratio

4.05

Quick ratio

2.91

Net debt/EBITDA

10.45

Margins
Efficiency
Dividend

EBITDA margin

6.5%

Gross margin

88.2%

Net margin

1.2%

Operating margin

-6.8%

Return on assets

0.5%

Return on equity

2%

Return on invested capital

1%

Return on capital employed

1.3%

Return on sales

2.4%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Sarepta Therapeutics stock price performed over time

Intraday

-0.05%

1 week

-0.21%

1 month

-6.65%

1 year

36.84%

YTD

49.27%

QTD

-8.9%

How have Sarepta Therapeutics's revenue and profit performed over time

Revenue

$1.4B

Gross profit

$1.24B

Operating income

-$94.83M

Net income

$16.9M

Gross margin

88.2%

Net margin

1.2%

The net income has soared by 103% QoQ and by 102% YoY

SRPT's net margin has surged by 103% since the previous quarter and by 101% year-on-year

SRPT's operating margin has soared by 89% YoY and by 68% from the previous quarter

SRPT's operating income has soared by 84% year-on-year and by 65% since the previous quarter

What is Sarepta Therapeutics's growth rate over time

What is Sarepta Therapeutics stock price valuation

P/E

351.07

P/B

14.05

P/S

9.64

EV/EBIT

427.42

EV/EBITDA

159.76

EV/Sales

10.37

The EPS has soared by 107% from the previous quarter and by 103% YoY

The company's equity rose by 35% YoY and by 12% QoQ

SRPT's P/B is 7% above its last 4 quarters average of 13.1 and 6% above its 5-year quarterly average of 13.3

The revenue rose by 44% YoY and by 13% QoQ

The P/S is 31% less than the 5-year quarterly average of 13.9 but 8% more than the last 4 quarters average of 8.9

How efficient is Sarepta Therapeutics business performance

The ROS has soared by 106% from the previous quarter and by 102% YoY

Sarepta Therapeutics's ROIC has soared by 106% from the previous quarter and by 103% YoY

The ROA has soared by 103% from the previous quarter and by 101% YoY

The return on equity has surged by 103% since the previous quarter and by 101% year-on-year

What is SRPT's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for SRPT.

How did Sarepta Therapeutics financials performed over time

The total assets is 42% more than the total liabilities

Sarepta Therapeutics's quick ratio has decreased by 26% YoY and by 8% from the previous quarter

The company's current ratio fell by 13% YoY but it rose by 2.5% QoQ

SRPT's debt is 44% greater than its equity

The company's equity rose by 35% YoY and by 12% QoQ

The debt to equity has declined by 20% year-on-year and by 10% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.